Number of eligible patients: CDEC discussed the uncertainty in the volume of people with moderately intense to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical authorities consulted by CADTH indicated that some patients who're classified as owning moderate or average illness might have a severe bleeding phenotype, which https://hemgenix05937.tkzblog.com/35517177/hemgenix-options